Statistical considerations in evaluating pharmacogenomics-based clinical effect for confirmatory trials.
about
Personalized medicine using DNA biomarkers: a reviewStatistical analysis of big data on pharmacogenomicsStratification and partial ascertainment of biomarker value in biomarker-driven clinical trials.Assessment and implication of prognostic imbalance in randomized controlled trials with a binary outcome--a simulation studyA composite model for subgroup identification and prediction via bicluster analysisEarly human screening of medications to treat drug addiction: novel paradigms and the relevance of pharmacogenetics.Systems pharmacology, pharmacogenetics, and clinical trial design in network medicineIntegrating biomarkers in clinical trials.Ethnic sensitive or molecular sensitive beyond all regions being equal in multiregional clinical trials.Regulatory perspective on remaining challenges for utilization of pharmacogenomics-guided drug developments.Characteristics of pharmacogenomics/biomarker-guided clinical trials for regulatory approval of anti-cancer drugs in Japan.A regulatory perspective on essential considerations in design and analysis of subgroups when correctly classified.Identifying treatment effect heterogeneity in clinical trials using subpopulations of events: STEPPThe value of control conditions for evaluating pharmacogenetic effects.Stratification of randomization is not required for a pre-specified subgroup analysis.
P2860
Q27022319-EFA531EC-587E-4139-B9AB-B1788EB05BFAQ30619237-8985ACC4-7206-40C9-B0D0-EF51FD5ABD52Q34036370-752DFDB8-AB3D-4670-9780-F7EF5C9388A8Q34281638-670E94EC-6E0F-4075-A135-17FA6352F5A2Q34408139-1655F632-79CF-40B3-BF91-1B7C21BA890EQ35282570-4D88554F-15F9-4606-A59E-02B41D2D5D35Q37199477-3828DFE2-F3B6-45CF-A390-503668E89E0AQ37853183-F77601FE-56A0-4722-A2A4-28D1D0AC07EBQ38040486-AC215630-3DFA-4D21-9578-5B70EFEB40A0Q38074713-3B15BBBA-D672-40D4-8E70-F58EC0C1EF1EQ38105254-23418CC1-5C49-49FA-B00D-A51C21D35994Q38176063-00EF1D73-0A30-4232-BC45-6EE649E88D1DQ40402182-269AED57-B732-437B-95F1-4FB35E0058C5Q42346078-41CC182B-0EDB-4D72-B43B-D0DD9B734C05Q44611904-B88885F9-102A-44F8-8119-CC39B8CB78F2
P2860
Statistical considerations in evaluating pharmacogenomics-based clinical effect for confirmatory trials.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Statistical considerations in ...... ffect for confirmatory trials.
@en
Statistical considerations in ...... ffect for confirmatory trials.
@nl
type
label
Statistical considerations in ...... ffect for confirmatory trials.
@en
Statistical considerations in ...... ffect for confirmatory trials.
@nl
prefLabel
Statistical considerations in ...... ffect for confirmatory trials.
@en
Statistical considerations in ...... ffect for confirmatory trials.
@nl
P2093
P2860
P356
P1433
P1476
Statistical considerations in ...... ffect for confirmatory trials.
@en
P2093
Hm James Hung
Robert T O'Neill
Sue-Jane Wang
P2860
P304
P356
10.1177/1740774510375455
P577
2010-07-01T00:00:00Z